Molecular Alterations Associated with Reduced 5-FU Sensitivity in mtDNA-Depleted HGC-27 Cells

Ozlem Turksoy Terzioglu1,2, Ayse Busranur Celik3, Gokhan Terzioglu4

  • 1Department of Molecular Biology and Genetics, Hamidiye Institute of Health Sciences, University of Health Sciences, Istanbul, Turkiye.

Abstract

Insights

Mitochondrial DNA (mtDNA) depletion in gastric cancer cells reduces sensitivity to 5-Fluorouracil (5-FU) chemotherapy. This mitochondrial dysfunction alters cell metabolism and signaling pathways, suggesting new therapeutic targets for overcoming chemoresistance.

Area of Science:

  • Cell Biology
  • Cancer Research
  • Mitochondrial Biology

Background:

  • Mitochondrial DNA (mtDNA) depletion is implicated in cancer progression and chemoresistance.
  • The role of mtDNA depletion in gastric cancer (GC) response to 5-Fluorouracil (5-FU) remains unclear.

Purpose of the Study:

  • To investigate the impact of mtDNA depletion on HGC-27 gastric cancer cell behavior.
  • To determine how mtDNA depletion affects sensitivity to 5-FU treatment.

Main Methods:

  • Established mtDNA-depleted HGC-27 cells.
  • Assessed cell viability, mitochondrial activity, gene/protein expression, and biochemical parameters after 5-FU treatment.
  • Utilized pharmacological inhibition and Raman spectroscopy to analyze pathway involvement and cellular response.

Main Results:

  • mtDNA-depleted cells showed decreased sensitivity to 5-FU, altered metabolism (glycolysis, pentose phosphate pathway), and G0/G1 cell cycle arrest.
  • Upregulation of HIF-1α, VEGF-A, IL-6, p21, and MAPK/ERK signaling was observed.
  • Inhibition of HIF-1α and MAPK/ERK pathways partially restored 5-FU sensitivity, indicating their role in adaptive resistance.

Conclusions:

  • mtDNA depletion induces a metabolically reprogrammed, stress-adapted phenotype in HGC-27 cells.
  • Mitochondrial genome loss contributes to 5-FU chemoresistance via altered HIF-1α and MAPK/ERK signaling.
  • Targeting mitochondrial stress pathways may offer strategies to enhance 5-FU efficacy in gastric cancer.